These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study]. Ai M; Yoshida M Nihon Rinsho; 2010 Nov; 68 Suppl 9():285-90. PubMed ID: 21661165 [No Abstract] [Full Text] [Related]
29. Zerumbone, a Bioactive Sesquiterpene, Ameliorates Diabetes-Induced Retinal Microvascular Damage through Inhibition of Phospho-p38 Mitogen-Activated Protein Kinase and Nuclear Factor-κB Pathways. Liu WY; Tzeng TF; Liu IM Molecules; 2016 Dec; 21(12):. PubMed ID: 27973425 [TBL] [Abstract][Full Text] [Related]
30. Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan. Lin YC; Chen YC; Horng JT; Chen JM Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32751875 [No Abstract] [Full Text] [Related]
31. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre. Tatlipinar S; Dinç UA; Yenerel NM; Görgün E Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975 [TBL] [Abstract][Full Text] [Related]
32. Fibrates and microvascular complications in diabetes--insight from the FIELD study. Ansquer JC; Foucher C; Aubonnet P; Le Malicot K Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980 [TBL] [Abstract][Full Text] [Related]
33. Relationship of retinal vascular calibre and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus: the Desheng Diabetic Eye Study. Yang X; Deng Y; Gu H; Ren X; Lim A; Snellingen T; Liu X; Wang N; Won Pak J; Liu N; Danis RP Br J Ophthalmol; 2016 Oct; 100(10):1359-65. PubMed ID: 26823397 [TBL] [Abstract][Full Text] [Related]
34. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Keating GM Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801 [TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina. Ding L; Cheng R; Hu Y; Takahashi Y; Jenkins AJ; Keech AC; Humphries KM; Gu X; Elliott MH; Xia X; Ma JX Am J Pathol; 2014 Oct; 184(10):2709-20. PubMed ID: 25108226 [TBL] [Abstract][Full Text] [Related]
37. Fenofibrate Ameliorates Oxidative Stress-Induced Retinal Microvascular Dysfunction in Diabetic Rats. Li J; Wang P; Chen Z; Yu S; Xu H Curr Eye Res; 2018 Nov; 43(11):1395-1403. PubMed ID: 30024319 [TBL] [Abstract][Full Text] [Related]
38. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. Ju HB; Zhang FX; Wang S; Song J; Cui T; Li LF; Zhang HY Medicine (Baltimore); 2017 Aug; 96(31):e7671. PubMed ID: 28767589 [TBL] [Abstract][Full Text] [Related]
39. Retinal venular tortuosity and fractal dimension predict incident retinopathy in adults with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Forster RB; Garcia ES; Sluiman AJ; Grecian SM; McLachlan S; MacGillivray TJ; Strachan MWJ; Price JF; Diabetologia; 2021 May; 64(5):1103-1112. PubMed ID: 33515071 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Chen Y; Hu Y; Lin M; Jenkins AJ; Keech AC; Mott R; Lyons TJ; Ma JX Diabetes; 2013 Jan; 62(1):261-72. PubMed ID: 23043158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]